Literature DB >> 20827288

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.

S Thepot1, J Zhou, A Perrot, M Robin, A Xhaard, R P de Latour, L Ades, P Ribaud, A D Petropoulou, R Porcher, G Socié.   

Abstract

Incidence on relapse and nonrelapse mortality (NRM) of chronic graft-versus-host disease (GVHD), per National Institutes of Health (NIH) criteria, is not well defined after reduced-intensity conditioning (RIC) regimens. We analyzed the association of chronic GVHD with the risk of relapse and NRM using Cox models in 177 consecutive patients who underwent transplantation for hematological malignancies after RIC. The cumulative incidence of chronic GVHD at 36 months was 74% when using Seattle's criteria compared with 54% with NIH consensus. In Cox model, NRM was significantly higher in patients with late-onset, persistent and recurrent acute GVHD (hazard ratio (HR): 6, 25 and 11; P = 0.014, P<0.0001, P<0.0001, respectively). The cumulative incidence of relapse was significantly decreased in patients with chronic GVHD compared with no GVHD group using either Seattle's or NIH criteria (HR 0.43 and 0.38; P = 0.022 and 0.016, respectively), whereas the presence of late-onset, persistent and recurrent acute GVHD was not associated with a decreased rate of relapse (HR: not significant, 0.70 and 0.71; P = not significant, P = 0.73 and P = 0.54, respectively). Chronic GVHD per NIH consensus definition is associated with the graft-versus-tumor effect, whereas all forms associated with acute features beyond day 100 are associated with NRM.

Entities:  

Mesh:

Year:  2010        PMID: 20827288     DOI: 10.1038/leu.2010.187

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  26 in total

1.  Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Edus H Warren; H Joachim Deeg; Rainer F Storb; Frederick R Appelbaum; Barry E Storer; Paul J Martin
Journal:  Blood       Date:  2011-06-01       Impact factor: 22.113

2.  Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.

Authors:  David A Jacobsohn; Mukta Arora; John P Klein; Anna Hassebroek; Mary E Flowers; Corey S Cutler; Alvaro Urbano-Ispizua; Brian J Bolwell; Joseph H Antin; Michael Boyiadzis; Jean-Yves Cahn; Mitchell S Cairo; Roger H Herzig; Luis M Isola; Thomas R Klumpp; Stephanie J Lee; Effie W Petersdorf; Stella Santarone; Robert P Gale; Harry C Schouten; Stephen R Spellman; Daniel J Weisdorf; John R Wingard; Mary M Horowitz; Steven Z Pavletic
Journal:  Blood       Date:  2011-08-30       Impact factor: 22.113

Review 3.  Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Frédéric Baron; Mohamad Mohty; Didier Blaise; Gérard Socié; Myriam Labopin; Jordi Esteve; Fabio Ciceri; Sebastian Giebel; Norbert Claude Gorin; Bipin N Savani; Christoph Schmid; Arnon Nagler
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

4.  Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Paul J Martin; Barry E Storer; Jeanne Palmer; Daniel J Weisdorf; Joseph Pidala; Mary E D Flowers; Mukta Arora; Madan Jagasia; Sally Arai; Xiaoyu Chai; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

5.  Disease severity in chronic graft-versus-host disease: doctors' gut feeling versus biostatistics?

Authors:  Gerard Socié
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

6.  Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies.

Authors:  M J Wondergem; F S Dijkstra; O J Visser; S Zweegman; G J Ossenkoppele; B I Witte; J J W M Janssen
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

Review 7.  Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.

Authors:  Hideki Nakasone; Bita Sahaf; David B Miklos
Journal:  Int J Hematol       Date:  2015-03-27       Impact factor: 2.490

8.  Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Authors:  Shernan G Holtan; Nandita Khera; John E Levine; Xiaoyu Chai; Barry Storer; Hien D Liu; Yoshihiro Inamoto; George L Chen; Sebastian Mayer; Mukta Arora; Jeanne Palmer; Mary E D Flowers; Corey S Cutler; Alexander Lukez; Sally Arai; Aleksandr Lazaryan; Laura F Newell; Christa Krupski; Madan H Jagasia; Iskra Pusic; William Wood; Anne S Renteria; Gregory Yanik; William J Hogan; Elizabeth Hexner; Francis Ayuk; Ernst Holler; Phandee Watanaboonyongcharoen; Yvonne A Efebera; James L M Ferrara; Angela Panoskaltsis-Mortari; Daniel Weisdorf; Stephanie J Lee; Joseph Pidala
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

9.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Boglarka Gyurkocza; Barry E Storer; Mohamed L Sorror; Karl Blume; Dietger Niederwieser; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; Firoozeh Sahebi; Edward D Agura; Parameswaran Hari; Benedetto Bruno; Peter A McSweeney; Michael B Maris; Richard T Maziarz; Amelia A Langston; Wolfgang Bethge; Lars Vindeløv; Georg-Nikolaus Franke; Ginna G Laport; Andrew M Yeager; Kai Hübel; H Joachim Deeg; George E Georges; Mary E D Flowers; Paul J Martin; Marco Mielcarek; Ann E Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

10.  A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.

Authors:  Brian Kornblit; David G Maloney; Barry E Storer; Michael B Maris; Lars Vindeløv; Parameswaran Hari; Amelia A Langston; Michael A Pulsipher; Wolfgang A Bethge; Thomas R Chauncey; Thoralf Lange; Finn B Petersen; Kai Hübel; Ann E Woolfrey; Mary E D Flowers; Rainer Storb; Brenda M Sandmaier
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.